Gil Y. Melmed, MD
Director, Clinical Trials, Cedars-Sinai Inflammatory Bowel Disease Center
Gil Y. Melmed, MD is Director of Clinical Trials at the Inflammatory Bowel Disease (IBD) Center at Cedars-Sinai. He also is a member of the Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute.
Dr. Melmed's main clinical and research interests are clinical outcomes in inflammatory bowel disease (Crohn's disease and ulcerative colitis), including health-related quality of life, post-operative outcomes, vaccination issues in patients with IBD, and why some patients with ulcerative colitis are subsequently diagnosed with Crohn's disease.
Dr. Melmed has authored or co-authored numerous articles for peer-reviewed publications, including Clinical Gastroenterology and Hepatology, the American Journal of Gastroenterology, Diseases of the Colon and Rectum, and Inflammatory Bowel Disease.
Dr. Melmed is a member of several professional organizations, including the American Gastroenterology Association and the American College of Gastroenterology. He co-chairs the Los Angeles Chapter Medical Advisory Committee of the Crohn's and Colitis Foundation of America, and serves on the Medical Advisory Committee to the IBD Support Foundation.
Dr. Melmed received his bachelor's degree from the University of Pennsylvania and his medical degree from Albert Einstein College of Medicine, where he was elected to Alpha Omega Alpha medical honors society. He completed his residency at Cedars-Sinai and his gastroenterology fellowship at the University of California, Los Angeles Medical Center, where he also received a master's of science in Clinical Research. He is board certified by the American Board of Internal Medicine in Gastroenterology and Internal Medicine.
Click here for a list of Dr. Melmed's research articles.